Evidence map›Paper›PMID 32466601›Full record

ArticleInternational journal of molecular sciences2020

New Tetrahydroacridine Hybrids with Dichlorobenzoic Acid Moiety Demonstrating Multifunctional Potential for the Treatment of Alzheimer's Disease.

Kamila Czarnecka, Małgorzata Girek, Przemysław Wójtowicz, Paweł Kręcisz, Robert Skibiński, Jakub Jończyk, Kamil Łątka, Marek Bajda, Anna Walczak, Grzegorz Galita and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Experiments and Calculation on New N,N-Molecules (Basel, Switzerland) · 2024
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kamila CzarneckaDepartment of Pharmaceutical Chemistry, Drug Analyses and Radiopharmacy, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, Poland.
Małgorzata GirekDepartment of Pharmaceutical Chemistry, Drug Analyses and Radiopharmacy, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, Poland.
Przemysław WójtowiczDepartment of Pharmaceutical Chemistry, Drug Analyses and Radiopharmacy, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, Poland.
Paweł KręciszDepartment of Pharmaceutical Chemistry, Drug Analyses and Radiopharmacy, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, Poland.
Robert SkibińskiDepartment of Medicinal Chemistry, Faculty of Pharmacy, Medical University of Lublin, Jaczewskiego 4, 20-090 Lublin, Poland.
Jakub JończykDepartment of Physicochemical Drug Analysis, Chair of Pharmaceutical Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland.ORCID 0000-0002-9731-908X
Kamil ŁątkaDepartment of Physicochemical Drug Analysis, Chair of Pharmaceutical Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland.
Marek BajdaDepartment of Physicochemical Drug Analysis, Chair of Pharmaceutical Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland.ORCID 0000-0001-6032-0354
Anna WalczakDepartment of Clinical Chemistry and Biochemistry, Medical University of Lodz, Narutowicza 60, 90-647 Lodz, Poland.
Grzegorz GalitaDepartment of Clinical Chemistry and Biochemistry, Medical University of Lodz, Narutowicza 60, 90-647 Lodz, Poland.
Jacek KabzińskiDepartment of Clinical Chemistry and Biochemistry, Medical University of Lodz, Narutowicza 60, 90-647 Lodz, Poland.ORCID 0000-0002-8358-3947
Ireneusz MajsterekDepartment of Clinical Chemistry and Biochemistry, Medical University of Lodz, Narutowicza 60, 90-647 Lodz, Poland.
Piotr SzymczykDepartment of Pharmaceutical Biotechnology, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, Poland.ORCID 0000-0002-7688-4717
Paweł SzymańskiDepartment of Pharmaceutical Chemistry, Drug Analyses and Radiopharmacy, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, Poland.ORCID 0000-0003-3438-7509

Funding

National Science Centre 2015/19/B/NZ7/02847
6 · The paper itself

Abstract

A series of new tetrahydroacridine and 3,5-dichlorobenzoic acid hybrids with different spacers were designed, synthesized, and evaluated for their ability to inhibit both cholinesterase enzymes. Compounds

Indexed as

Alzheimer DiseaseAmyloid beta-Protein PrecursorAnimalsCatalytic DomainCell Line, TumorCells, CulturedChlorobenzoatesCholinesterase InhibitorsCholinesterasesFree Radical ScavengersHumansHyaluronoglucosaminidaseMiceMolecular Docking SimulationNeuroprotective AgentsProtein BindingAmyloid beta-Protein PrecursorChlorobenzoatesCholinesterase InhibitorsCholinesterasesFree Radical ScavengersHyaluronoglucosaminidaseNeuroprotective AgentsTacrineacetylcholinesterase inhibitorsAlzheimer’s diseaseEllman’s methodmolecular modeling

Identifiers

PMID32466601
PMCPMC7312527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.